Viridian Therapeutics, Inc. announced the promotion of Dr. Thomas Ciulla, M.D., M.B.A. to Chief Medical Officer to succeed Dr. Barrett Katz, M.D., M.B.A. Dr. Katz will continue to work with Viridian as a consultant to the company. Dr. Ciulla joined Viridian in early 2023 as Chief Development Officer, where he has been leading the clinical development efforts for all programs. Dr. Ciulla has held numerous leadership roles in medical and clinical development and research, including serving most recently as Chief Medical Officer and Chief Development Officer of Clearside Bio prior to joining Viridian.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.6 USD | +5.59% | -4.90% | -37.56% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.56% | 822M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Viridian Therapeutics, Inc. Announces Executive Changes